Latest News & Features
Americas
Office declined application citing earlier authorisations for human inhalers containing same ingredient | Boehringer argued that ciclesonide was a ‘new active substance’ not previously authorised for a veterinary product in the EU. 8 July 2025
Americas
German and Finnish pharma giants sue Indian rival in Delaware court | Dispute centres on generic bid for prostate cancer blockbuster | Suit follows leadership shakeup at Bayer. 8 July 2025
Europe
The architect of an historic change in the way patent claims are interpreted explains what it means for AI drafting, and why more harmonisation may follow, reports Tom Phillips 3 July 2025
Europe
Board of Appeal upholds opposition challenge over added subject-matter claims | Dispute concerned patent relating to T cell therapeutic manufacturing methods. 3 July 2025
Americas
Biocon failed to provide critical information about proposed denosumab product, Amgen claims | Company expects ‘sales erosion’ of Prolia and XGEVA in 2025 driven by biosimilar competition | Sandoz launched interchangeable versions of bone drugs last month following settlement in 2024. 2 July 2025
Europe
The prominent senior IP judge is known for his groundbreaking judgments on patents, AI and FRAND, such as Unwired Planet, Thaler's DABUS, and InterDigital. 2 July 2025
Americas
Judge says sale of genetic data is ‘scary proposition’ but that blanket ban could result in missed opportunities | Former CEO Anne Wojcicki will repurchase business that she co-founded and ran for years. 1 July 2025
Europe
French biopharma giant overturns German rival’s patent at the European Patent Office | Revocation based on insufficient disclosure of antibody production | Appeal focused on detection method claims and biomarker specificity. 1 July 2025
Careers
Veteran leader to stay on during transition period as adviser until his retirement later this year. 1 July 2025
Americas
This session brings together experts from Choate, Radius Health, and Syros Pharmaceuticals to examine the current policy landscape affecting life sciences patents. Discussions focus on recent developments such as the Inflation Reduction Act’s drug pricing provisions and concerns over patent examination quality at the USPTO. 30 June 2025